Andrej BABIC PhD
Justyna PLEWKA MA
Nathalie STRANSKY PhD
Duc TRAN MSc
Bams ABILA PhD
KOL in COPD
& lung cancer cachexia
in cancer cachexia
Andrej is the Chief Executive Officer and co-founder of Adiposs. He holds a master’s degree in pharmaceutical sciences and a PhD in pharmaceutical chemistry. Andrej is the co-inventor of ImageBAT. He was a senior lecturer in pharmaceutics at the University of Geneva, where he developed molecules for diagnosis of diabetes, obesity and cancer. Andrej has co-authored more than 30 scientific papers and holds several patents in the fields of medical imaging, photodynamic therapy and nanotechnology. He has worked in the field of diagnostic medical imaging for over 10 years leading multidisciplinary teams and projects in academia and start-up companies.
Justyna is the Chief Operating Officer and co-founder of Adiposs. She has a double master’s degree in Business Administration & Management and in International Economic Relations and over 10 years of extensive business, finance and competitive intelligence experience. She has spent a big part of her professional life working at KPMG where she provided audit, consulting, advisory and due diligence services to a wide range of public and private companies in multiple jurisdictions.
Nathalie is the Chief Technical Officer of Adiposs. She holds a master’s degree in pharmacy and a PhD in pharmaceutical technology from the University of Geneva. She is responsible for preclinical development of ImageBAT and GMP production. Nathalie has 10 years of experience in the development of advanced nanotechnology pharmaceutical systems and medical imaging agents in academia and start-up companies. She also has experience in designing clinical trials and is coordinating activities of the clinical pipeline of Adiposs.
Duc brings to Adiposs over twenty years of experience in drug discovery and drug development from big pharma companies (Sanofi-Aventis, Pfizer, Lundbeck) and biotech start-ups (Preglem, Arisgen, EspeRare, Prexton Therapeutics). Duc’s experience extends across multiple therapeutic areas including cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease and reproductive medicine. He has successfully delivered a number of projects into clinical development, up to registration. At Adiposs, Duc is responsible for providing IND-enabling Preclinical, Early Clinical, and Chemistry, Manufacturing and Control (CMC) leadership to support regulatory submissions.
Bams is a UK-registered physician and clinical scientist with specializations in clinical pharmacology and pharmaceutical medicine. He has over 15 years of experience in clinical medicine and medical research and over 30 years of experience in global drug development leadership roles in Aventis, Pfizer, Astellas, AstraZeneca and GSK. Bams was involved in the translational science activities and clinical development of small molecule drugs in multiple therapy areas, including urology, oncology, cardiovascular and neurology. After that, his focus has been the development of biologics and advanced therapy medicinal products (ATMPs) in several therapy areas including oncology, immuno-inflammation, neurology, respiratory disorders and diabetes.
Christine Deuschel has more than 25 years of Biotech and MedTech experience in pharma and start-up companies. Since 2020, she has been independent director at Adiposs bringing oversight and constructive challenge to the executive team.
She serves as Senior Advisor of Fongit foundation, the start-up incubator in Geneva, and Venturelab Trainer for the Innosuisse Start-up Training in Biotech. Christine is also active in several Biotech and MedTech start-ups.
Christine has held several senior executive positions and served as board member and chair in diagnostic companies including Biocartis SA Switzerland and Belgium, which had a successful IPO with €100M raised in 2015.
Christine served as Vice President of Foundation Eclosion, the incubator of Life Sciences in Geneva. She was Senior Vice President of the Project & Portfolio Management Office at Debiopharm International SA Switzerland where she was responsible for a portfolio of drug development projects in the fields of oncology, pain, and autoimmune and infectious diseases.
Christine holds an MBA from HEC and the Swiss Federal Institute of Technology Lausanne, and a PhD in Science from the University of Fribourg, Switzerland. She completed post-doctoral studies at the University of California at Berkeley.
Pierre A. Morgon is CEO of MRGN Advisors, Regional Partner for Switzerland at Mérieux Equity Partners and Senior Vice President International Business at CanSino Biologics.
He is Chairman of the Boards of Theradiag, Eurocine Vaccines, MYCB1 and Health Technologies Holding, as well as Non-Executive Director to the Boards of Vaccitech, Univercells and Adiposs.
Pierre has over 30 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies.
He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies.
He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.
Annemie Schols is Professor of Nutrition and Metabolism in Chronic Diseases at Maastricht University, the Netherlands.
Since 2006, professor Schols has been Head of NUTRIM School of Nutrition and Translational Research in Metabolism. Under her leadership, NUTRIM has grown into a worldwide Center of Excellence for research in the fields of obesity, diabetes, COPD and cancer cachexia.
In 2020, professor Schols was appointed as dean of the Faculty of Health, Medicine and Life Sciences (FHML) of Maastricht University and Vice President Executive Board of Maastricht University Medical Centre.
Professor Schols is principal investigator of a translational research program on metabolic derangements in COPD and lung cancer with a specific focus on unintended weight loss and muscle wasting, to unravel generic and disease specific denominators and mechanisms. These insights are the basis for developing and evaluating novel nutritional and metabolic intervention strategies with a focus on multimodal approaches.
Annemie Schols has published more than 350 international scientific publications and over 50 book contributions. Her Hirsch citation index is 107.
Josep M. Argilés is Professor of Biochemistry and Molecular Biology of Cancer at the Faculty of Biology, University of Barcelona, Spain, being the leader of a research group interested in cancer cachexia.
His main contribution to the field of cancer research concerns the mechanisms associated with cancer cachexia. Prof. Argilés was the first scientist to describe the mechanism responsible for the increased protein breakdown in skeletal muscle of cancer patients which seems to be responsible for muscle wasting.
He is responsible for the introduction of the concept of the cytokine balance of the cancer patient, the ratio of the pro-cachectic (TNF-a, IL-6, g-IFN…) to anti-cachectic (IL-10, sTNFRs…) cytokines.
In addition to his work in describing mechanisms and mediators of cancer cachexia, Prof. Argilés has made interesting contributions in the form of pre-clinical studies regarding the pharmacological treatment of cachexia using different therapeutic strategies such as b2-agonists or anabolic cytokines, such as IL-15.
Josep M. Argilés has published more than 300 international scientific publications. His Hirsch citation index is 83.